ZYGFLOVI
Live / Allowed — Third extension granted (statement of use) (as of 08 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 16 Jan 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98359121
- Mark type
- Word mark
- Filed
- 16 Jan 2024
- Published for opposition
- 17 Sept 2024
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations based upon human allogeneic bone marrow mesenchymal stem cell derived extracellular vesicles (EVs) containing secretomes for the treatment of immunomodulatory, inflammatory, or autoimmune conditions such as respiratory diseases, neurological diseases, tissue injury and repair, gastrointestinal diseases, joint diseases and transplant.
Owner
- Direct Biologics LLC, Austin, TX, US
- Direct Biologics LLC, Austin, TX, US
Prosecution history
- 11 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 May 2026 — SOU EXTENSION 3 GRANTED
- 05 May 2026 — SOU EXTENSION 3 FILED
- 06 May 2026 — SOU TEAS EXTENSION RECEIVED
- 01 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Apr 2026 — SOU EXTENSION 2 GRANTED
- 30 Oct 2025 — SOU EXTENSION 2 FILED
- 27 Apr 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 31 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Jun 2025 — ASSIGNED TO EXAMINER
- 17 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Apr 2025 — SOU EXTENSION 1 GRANTED
- 16 Apr 2025 — SOU EXTENSION 1 FILED
- 16 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT